Infinity Pharmaceuticals Inc INFIQ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.26
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $90.76
- Volume/Avg
- 1,002 / 13,261
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.00
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Infinity Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology related treatments. The company operates in only one segment which is drug development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 30
- Website
- https://www.infi.com
Valuation
|
Metric
|
INFIQ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.00 |
Price/Cash Flow | — |
Price/Earnings
INFIQ
Financial Strength
|
Metric
|
INFIQ
|
|---|---|
Quick Ratio | 1.47 |
Current Ratio | 1.65 |
Interest Coverage | −226.49 |
Quick Ratio
INFIQ
Profitability
|
Metric
|
INFIQ
|
|---|---|
Return on Assets (Normalized) | −87.96% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
INFIQ
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lfrjqszww | Fhjr | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gpgqhfw | Ytrww | $108.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mbphbcx | Bgjjq | $105.3 Bil | |
MRNA
| Moderna Inc | Wlzntrnf | Szqlq | $47.0 Bil | |
ARGX
| argenx SE ADR | Wvrvnqxqk | Plbp | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ddgvjqqq | Ycs | $22.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cttrtdmx | Lvbkvm | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jksqjqfbp | Vrgzr | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hbvttqhrx | Rjzjhn | $12.6 Bil | |
INCY
| Incyte Corp | Qymtlsz | Gckpp | $12.0 Bil |